Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Figdor
Carl Figdor, Den Bosch NL
| Patent application number | Description | Published |
|---|---|---|
| 20090156786 | Mammalian Genes: Related Reagents and Methods - Purified genes encoding proteins from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided. | 06-18-2009 |
| 20100261190 | Mammalian Genes; Related Reagents and Methods - Purified genes encoding proteins from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided. | 10-14-2010 |
Carl Gustav Figdor, Den Bosch NL
| Patent application number | Description | Published |
|---|---|---|
| 20090035300 | IMMUNOMODULATION OF DENDRITIC CELLS - The present invention relates to isolated nucleic acid molecule encoding the transcription regulator DC-SCRIPT or a derivative thereof. The invention further relates to its use in therapy and to compound for interfering with the biological function of the transcription factor DC-SCRIPT. Such compounds can be compounds interfering with expression of DC-SCRIPT; or compounds interfering with binding of DC-SCRIPT to DNA. | 02-05-2009 |
| 20090285839 | Antigen uptake receptor for candida albicans on dendritic cells - Dendritic cells (DC) that express the type II C-type lectin DC-SIGN (CD209) are located in the submucosa of tissues, where they mediate HIV-1 entry. Interestingly, the pathogen | 11-19-2009 |
Carl Gustav Figdor, 'S-Hertogenbosch NL
| Patent application number | Description | Published |
|---|---|---|
| 20090286221 | Device Comprising a Container System for a Bodily Fluid - The invention relates to a device for separating a bodily fluid, in particular blood platelet concentrate, into fractions under centrifugal force. The device comprises a flexible container system which comprises at least a first container for the fluid to be separated and a second container for a separated fraction, wherein the containers are mutually connected using a connecting conduit for a fluid, wherein a widened portion is arranged in the connecting conduit between the first and second container, wherein during use a detectable separating layer is created in the widened portion. The invention also relates to a flexible container system intended for the device, a method for separating blood platelet concentrate into fractions under centrifugal force, and a blood platelet concentrate with low leukocyte content. | 11-19-2009 |
Carl Gustav Figdor, Hertogenbosch NL
| Patent application number | Description | Published |
|---|---|---|
| 20090232839 | MELANOMA ASSOCIATED PEPTIDE ANALOGUES AND VACCINES AGAINST MELANOMA - The present invention is concerned with cancer treatment and diagnosis, especially with melanoma associated peptide analogues with improved immunogenicity, epitopes thereof, vaccines against melanoma, tumor infiltrating T lymphocytes recognizing the antigen and diagnostics for the detection of melanoma and for the monitoring of vaccination. The peptides according to the invention can be exploited to elicit native epitope-reactive Cm. Usage of the peptides with improved immunogenicity may contribute to the development of CTL-epitope based vaccines in viral disease and cancer. | 09-17-2009 |
| 20110135675 | MELANOMA ASSOCIATED PEPTIDE ANALOGUES AND VACCINES AGAINST MELANOMA - The present invention is concerned with cancer treatment and diagnosis, especially with melanoma associated peptide analogues with improved immunogenicity, epitopes thereof; vaccines against melanoma, tumor infiltrating T lymphocytes recognizing the antigen and diagnostics for the detection of melanoma and for the monitoring of vaccination. The peptides according to the invention can be exploited to elicit native epitope-reactive Cm. Usage of the peptides with improved immunogenicity may contribute to the development of CTL-epitope based vaccines in viral disease and cancer. | 06-09-2011 |